# MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia

> **NCT05464784** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **MediciNova** · enrollment: 40 (estimated)

## Conditions studied

- Diabetes Mellitus, Type 2
- Hypertriglyceridemia
- Non-Alcoholic Fatty Liver Disease

## Interventions

- **DRUG:** MN-001
- **DRUG:** MN-001 placebo

## Key facts

- **NCT ID:** NCT05464784
- **Lead sponsor:** MediciNova
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-08-22
- **Primary completion:** 2026-12-31
- **Final completion:** 2026-12-31
- **Target enrollment:** 40 (ESTIMATED)
- **Last updated:** 2026-02-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05464784

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05464784, "MN-001 in Non-alcoholic Fatty Liver Disease, Type 2 Diabetes Mellitus, and Hypertriglyceridemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05464784. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*